



11th October 2016

## BG's Wake Up Call

	Last close	Daily chg (%)	Chg YTD (%)
<b>Indices</b>			
Dow Jones	18329.04	+0.49%	+5.19%
S&P 500	2163.66	+0.46%	+5.86%
Nasdaq	5328.67	+0.69%	+6.42%
Nikkei	17024.76	+0.98%	-11.42%
Stoxx 600	341.977	+0.69%	-6.52%
CAC 40	4497.26	+1.06%	-3.01%
<b>Oil /Gold</b>			
Crude WTI	51.35	+3.09%	+38.04%
Gold (once)	1259.81	+0.51%	+18.58%
<b>Currencies/Rates</b>			
EUR/USD	1.1157	-0.17%	+2.71%
EUR/CHF	1.09715	+0.22%	+0.90%
German 10 years	-0.011	-78.03%	-101.69%
French 10 years	0.293	+15.81%	-70.17%
Euribor	-	+-%	+-%

### Economic releases :

Date	
11th-Oct	EUR - Euro Zone ZEW Survey (Economic Sentiment - OCT) CAD - Housing Stats (SEP)

### Upcoming BG events :

Date	
21st-Oct	KORIAN (BG Geneva roadshow with CFO)
28th-Oct	IMERYS (Paris roadshow)
8th-Nov	LVMH (BG Luxembourg roadshow with IR)
14th-Nov/ 15th-Nov	4th Paris Healthcare Conference
18th-Nov	ENGIE (BG Luxembourg roadshow with IR)
24th-Nov	IMERYS (BG London roadshow with IR)

### Recent reports :

Date	
7th-Oct	ALTICE Lower risk profile
7th-Oct	SAINT GOBAIN : Endless sluggishness is not our scenario (report released today)
4th-Oct	CASINO We are cautious ahead of Q3 figures
4th-Oct	LAFARGE HOLCIM This is still a Buy
15th-Sept	Remy Cointreau : It keeps getting better
14th-Sept	Automotive Innovation: the only way to stand out!

List of our Reco & Fair Value : Please click here to download



### AB INBEV

**BUY vs. NEUTRAL, Fair Value EUR124 vs. EUR109 (+8%)**

*Fox in the Hen House (report released today)*

As the acquisition of SABMiller is finalised, there is already speculation on what the next target could be for AB InBev (AB InBev has an internal target to reach USD100bn in revenues by 2022). Although we believe that the case for Coca-Cola is stronger than that for PepsiCo, investors wanting to benefit from the transformation of AB InBev into a drinks company (from a brewer) are probably best to buy shares in AB InBev rather than those of any potential targets.

### IPSEN

**BUY-Top Picks, Fair Value EUR67 (+6%)**

*A full case vs a single sentence*

At ESMO principal investigator presented quite convincing phase II data for cabozantinib in 1L RCC that could be the base of a supplement filing ... despite a more balanced view from discussant.

### LVMH

**BUY, Fair Value EUR171 (+9%)**

*Q3 sales grew 6% organically, significantly above consensus*

LVMH reported Q3 sales of EUR9.14bn yesterday (cs: EUR8.93bn), up 4% and 6% organically (cs:+4%). This highlighted a clear acceleration versus Q2 and H1 (both at +4% organically). Note the very good performance by the F&L division (+5% in Q3). We are maintaining our Buy recommendation with an unchanged EUR171 FV.

### In brief...

**SPIRITS, LVMH's Q3 sales ( what read-across for European spirits groups?)**

Food & Beverages

**AB InBev**

Price EUR115.05

**Fox in the Hen House (report released today)**

**Fair Value EUR124 vs. EUR109 (+8%)**

**BUY vs. NEUTRAL**

Bloomberg	ABI BB
Reuters	ABI.BR
12-month High / Low (EUR)	123.3 / 98.4
Market Cap (EURm)	185,028
Ev (BG Estimates) (EURm)	265,171
Avg. 6m daily volume (000)	1,420
3y EPS CAGR	6.3%

As the acquisition of SABMiller is finalised, there is already speculation on what the next target could be for AB InBev (AB InBev has an internal target to reach USD100bn in revenues by 2022). Although we believe that the case for Coca-Cola is stronger than that for PepsiCo, investors wanting to benefit from the transformation of AB InBev into a drinks company (from a brewer) are probably best to buy shares in AB InBev rather than those of any potential targets.

**ANALYSIS**

- Given the obvious strengths of AB InBev in cost-cutting and distribution, and the limited remaining possibilities in beer, consolidation in soft drinks might be the next step for the company. AB InBev would become a drinks business, rather than just a brewer, delivering more self-help with the potential cost and revenue benefits of selling beer and soft drinks through the same distribution system.
- Soft drinks and beer seem to have the same profile in terms of growth (i.e. 5% p.a. over the medium term), drivers (population growth, rising incomes and middle classes) and profitability (PepsiCo Beverages and the Coca-Cola system has operating margins of respectively 14% and 16%, which compares well with any brewer). However, AB InBev does better with an operating margin of 31% in beer and has already the credentials to do the same in soft drinks (Brazil's soft drinks margin of 44%).
- We believe that the case for The Coca-Cola Company is more convincing than that for PepsiCo, as Coca-Cola is the stronger soft drinks brand and has plenty of opportunities to drive share growth in still non-alcoholic beverages. Furthermore, it offers additional prospects of buying out the bottlers (which have been separated from the main company) at much lower valuations. Integrating the entire Coca-Cola system sets AB InBev on its way to USD300bn in revenues by 2030.
- We are increasing our 2017 operating profit and EPS by about 4% to take into account the resurgence of some emerging market currencies against the USD (ytd BRL +25%, ZAR +20%, COP+15%). Our DCF-based fair value of EUR124 is computed using a risk free rate of 1.6%, a risk premium of 7.0% and a Beta of 0.95.

	1 M	3 M	6 M	31/12/15
Absolute perf.	3.6%	-0.8%	7.7%	0.6%
Food & Bev.	-1.4%	-1.7%	2.2%	-1.8%
DJ Stoxx 600	-1.0%	4.5%	3.1%	-6.5%

YEnd Dec. (USDm)	2015	2016e	2017e	2018e
Sales	43,604	43,044	58,284	60,870
% change		-1.3%	35.4%	4.4%
EBITDA	16,921	16,643	23,847	25,688
EBIT	13,768	13,565	19,891	21,609
% change		-1.5%	46.6%	8.6%
Net income	8,513	7,532	11,123	12,210
% change		-11.5%	47.7%	9.8%

	2015	2016e	2017e	2018e
Operating margin	31.6	31.5	34.1	35.5
Net margin	19.5	17.5	19.1	20.1
ROE	20.2	17.5	12.9	13.5
ROCE	10.1	10.1	10.4	8.6
Gearing	98.7	101.7	97.0	89.5

(USD)	2015	2016e	2017e	2018e
EPS	5.10	4.52	5.58	6.12
% change	-	-11.5%	23.5%	9.8%
P/E	25.2x	28.4x	23.0x	21.0x
FCF yield (%)	3.6%	3.0%	5.4%	4.9%
Dividends (USD)	2.68	2.37	2.93	3.21
Div yield (%)	2.1%	1.8%	2.3%	2.5%
EV/Sales	6.7x	6.9x	5.8x	5.5x
EV/EBITDA	17.2x	17.8x	14.1x	13.0x
EV/EBIT	21.1x	21.8x	16.9x	15.4x

[Click here to download](#)



**Analyst :**  
 Nikolaas Faes  
 33(0) 6 11 12 44 44  
 nfaes@bryangarnier.com

**Sector Team :**  
 Loic Morvan  
 Antoine Parison  
 Cédric Rossi  
 Virginie Roumage

Healthcare

**Ipsen**

Price EUR63.22

**A full case vs a single sentence**

Fair Value EUR67 (+6%)

BUY-Top Picks

**At ESMO principal investigator presented quite convincing phase II data for cabozantinib in 1L RCC that could be the base of a supplement filing ... despite a more balanced view from discussant.**

**ANALYSIS**

- What we are doing here is the summarized feedback from the third day at ESMO since CABOSUN phase II data were in highlight at the Presidential session.
- CABOSUN recruited 150 patients with clear-cell RCC naïve to therapy and having a poor or intermediate risk i.e. having the poorer prognosis (in 2L they will have between 5.4 and 16.6 months median survival rate), including 37% with bone metastases. This population represents between 70 and 75% of the overall RCC population.
- The primary endpoint was median PFS and it was expanded from 5.6 to 8.2 months (HR=0.69, p=0.012), with benefit across all subgroups, although it is fair to say that those with bone metastases benefited the most. The difference in ORR was also outstanding at 46% vs 18% (when assessed by investigator). Dose reductions occurred in 58% and 49% respectively in the cabo arm and the sunitinib arm and grade 3-4 side effects appeared very comparable across the two arms (65% vs 68%) and grade 5 AEs unfrequent (5% vs 4%). So these are very strong and consistent data in a setting where nothing has emerged since a long time.
- Everything was good until the last part of the presenter's speech when he stated that, based on the absence of median OS benefit (HR=0.80 with 30.3 months vs 21.8 but p=NS), he would not be comfortable prescribing the drug in 1L until confirmatory data from a phase III trial. This has come as a very unexpected comment from one of the most respected specialists in Europe. Exactly at that time, Exelixis's share price collapsed in the US.
- Asked similarly about what they would do, three US specialists invited by Ipsen and Exelixis went against this conclusion. They showed that sunitinib very much did as expected in this trial and like in previous ones and despite a limited follow-up, OS benefit is likely to be confirmed later. In any case, with a clear benefit on mPFS and ORR, cabozantinib proves superior to sunitinib and time will tell about nivolumab and others in this setting. In PC trials, it has been showed that cabozantinib might well prepare the milieu or make the environment permissive for a better effect of an IO drug. So cabo first makes a lot of sense, even though safety can be called into question. But patients might prefer an oral drug. Lastly, some preliminary phase I data, mostly in bladder cancers, showed interesting efficacy and safety data in heavily pre-treated patients that are reassuring for the safety of the combination and convinced Exelixis to start a phase II trial in bladder cancer. Cabo+Nivo vs Cabo then Nivo looks like an interesting phase III to perform.
- So, in the end, our belief is that cabozantinib, whatever its precise setting, is here to play a key role in RCC. Because of its mode of action that not only involves VEGFR pathway but also MET and AXL, it is now the TKi of choice and it is a bit too early to say how IO will navigate around. Moreover, 5-10% of patients that have immune diseases are not eligible to IO and those with bone mets are also clear candidates for cabo. So, the size of the market opportunity remains to be carefully measured but CABOSUN data are clearly helpful to give cabozantinib a central place in RCC.

**VALUATION**

- What can now happen with 1L RCC? Well, the optimism to be able to file on phase II data has clearly increased at Exelixis and Ipsen. The ability to file by the end of H1 2017 and to have a variation procedure in Europe making it possible to get an approval by year-end 2018 is real. This would be a major upside to our scenario and although the median duration of treatment based on mPFS might not be massively increased by getting in 1L, it is said that about 40% of patients are lost between 1L and 2L, thus reducing dramatically the target population.
- We will reassess our main assumptions at a later stage.

**NEXT CATALYSTS**

Bloomberg	IPN.FP
Reuters	IPN.PA
12-month High / Low (EUR)	63.6 / 47.1
Market Cap (EUR)	5,264
Ev (BG Estimates) (EUR)	5,352
Avg. 6m daily volume (000)	75.50
3y EPS CAGR	13.8%

	1 M	3 M	6 M	31/12/15
Absolute perf.	8.3%	20.9%	21.3%	3.6%
Healthcare	-0.6%	-4.9%	0.6%	-9.5%
DJ Stoxx 600	-1.0%	4.5%	3.1%	-6.5%

YEnd Dec. (€m)	2015	2016e	2017e	2018e
Sales	1,444	1,566	1,714	1,866
% change		8.5%	9.4%	8.9%
EBITDA	366	407	462	544
EBIT	322.5	340.9	390.0	466.3
% change		5.7%	14.4%	19.5%
Net income	228.0	237.3	278.0	335.6
% change		4.1%	17.2%	20.7%

	2015	2016e	2017e	2018e
Operating margin	22.3	21.8	22.8	25.0
Net margin	12.5	14.0	14.1	15.9
ROE	15.5	16.9	16.7	17.8
ROCE	22.6	17.6	19.6	22.8
Gearing	-8.3	6.4	-0.2	-9.2

(€)	2015	2016e	2017e	2018e
EPS	2.78	2.89	3.39	4.09
% change	-	4.1%	17.2%	20.7%
P/E	22.7x	21.8x	18.6x	15.4x
FCF yield (%)	3.4%	3.7%	4.5%	5.5%
Dividends (€)	0.85	0.85	1.10	1.20
Div yield (%)	1.3%	1.3%	1.7%	1.9%
EV/Sales	3.6x	3.4x	3.1x	2.7x
EV/EBITDA	14.1x	13.2x	11.4x	9.4x
EV/EBIT	16.0x	15.7x	13.5x	10.9x



**Analyst :**  
 Eric Le Berrigaud  
 33(0) 1 56 68 75 33  
 eleberrigaud@bryangarnier.com

**Sector Team :**  
 Mickael Chane Du  
 Hugo Solvet

Luxury & Consumer Goods

**LVMH**

Price EUR157.05

Q3 sales grew 6% organically, significantly above consensus

Fair Value EUR171 (+9%)

BUY

Bloomberg	MC FP
Reuters	LVMH.PA
12-month High / Low (EUR)	173.5 / 131.4
Market Cap (EUR)	79,741
Ev (BG Estimates) (EUR)	82,861
Avg. 6m daily volume (000)	773.3
3y EPS CAGR	11.2%

LVMH reported Q3 sales of EUR9.14bn yesterday (cs: EUR8.93bn), up 4% and 6% organically (cs:+4%). This highlighted a clear acceleration versus Q2 and H1 (both at +4% organically). Note the very good performance by the F&L division (+5% in Q3). We are maintaining our Buy recommendation with an unchanged EUR171 FV.

**ANALYSIS**

- Q3 2016 sales grew 6% organically to EUR9.14bn (consensus: EUR8.93bn and +4% organic growth), implying a 5% increase over 9M (EUR26.3bn). Note the 4% sales increase of the **Wines & Spirits** division (13% of group sales) following +13% in Q2 and +9% in H1. This expected slowdown was due to a very demanding comparison basis particularly at Hennessy (+16% in Q3 2015 of which +23% for Cognac). Hennessy volumes grew 9% over 9m vs +13% in H1. The very welcome news from the release stemmed from **Fashion & Leather goods** (34% of LVMH sales), which grew 5% in Q3 following +1% in Q2 and even +0% in H1. We guess that Louis Vuitton revenues increased at least 4%, a level which allows the brand to improve its profitability, and the F&L performance was achieved despite the negative impact of the US brands (Marc Jacobs and Donna Karan). And Fendi continued to perform very well.

- Performances by the three other businesses were also very strong on the whole with for instance, +10% for **Perfumes & Cosmetics** in Q3 (after +6% in Q2 and +8% in H1) thanks to market share gains particularly at Christian Dior Parfums in all geographical areas, while **Watches & Jewelry** sales (9% of Group sales) were up 2% during the quarter, with no acceleration vs Q2, driven by Bulgari and Tag Heuer's positive performances, despite a tough watches environment. Lastly, **Selective Retail** activity (32% of revenues) enjoyed an 8% increase in Q3 (+7% in Q2), despite the decline in DFS sales (Hong Kong and Macau had a strong negative impact) but thanks to Sephora's clear dynamism (double digit sales increase) and market share gains in almost every region.

**Quarterly organic sales growth by division**

in %	Q4 15	Q1 16	Q2 16	H1 16	Q3 16	9M 16
Wines & Spirits	4	6	13	9	4	7
Fashion & Leather	3	0	1	0	5	2
Perfumes & Cosmetics	7	9	6	8	10	8
Watches & Jewelry	3	7	2	4	2	4
Selective Retail	5	4	7	5	8	6
<b>Group</b>	<b>5</b>	<b>3</b>	<b>4</b>	<b>4</b>	<b>6</b>	<b>5</b>

Source : Company Data; Bryan Garnier & Co. ests.

- Although the group's management did not disclose sales momentum by geographical area yesterday (this should be done today during the conference call at 3pm), we guess that revenues were globally well oriented in **North America**, in line with Q2 (+7%), thanks especially to Hennessy, Sephora and Tag Heuer while **Europe** should grow modestly (+3% in Q2), penalised by France despite some improvement in others European countries, not to mention the UK (GBP decline). Momentum in **Japan** (7% of sales) was probably still very poor (-5% in Q2) since the strength of the JPY means fewer Chinese tourist are visiting Japan and the Japanese are buying more overseas (mainly in Korea and Hawaii for instance). We anticipate a significant acceleration in **APAC** (27% of sales). Momentum should have improved for F&L while Hennessy's slowdown clearly had a negative impact. Globally, the situation in **Mainland China** is improving (the Chinese are buying more at home than before) although it remains very challenging both in Hong Kong and Macao. APAC sales were down 2% in Q1 and up 3% in Q2.

**VALUATION**

- The LVMH share has gained 9% YTD (+0% for luxury average) and the stock is trading at 12.1x 2016 EV/EBIT, an 11% discount vs the peer average. We are maintaining our buy recommendation with an unchanged EUR171 FV.

**NEXT CATALYSTS**

- Today conference call at 3pm

[Click here to download](#) [Click here to download](#)



**Analyst :**  
Loic Morvan  
33(0) 1 70 36 57 24  
lmorvan@bryangarnier.com

**Sector Team :**  
Nikolaas Faes  
Antoine Parison  
Cédric Rossi  
Virginie Roumage

## Sector View

## Spirits

## LVMH's Q3 sales à what read-across for European spirits groups?

	1 M	3 M	6 M	31/12/15
Food & Bev.	-1.4%	-1.7%	2.2%	-1.8%
DJ Stoxx 600	-1.0%	4.5%	3.1%	-6.5%

\*Stoxx Sector Indices

## Companies covered

CAMPARI	BUY	EUR10,5
DIAGEO	NEUTRAL	2100p
PERNOD RICARD	NEUTRAL	EUR112
REMY COINTREAU	BUY	EUR84

## ANALYSIS

- Yesterday LVMH reported that its Wine & Spirits division increased 4% organically in Q3, implying a deceleration vs Q2 (+13%) and Q1 (+6%). This reflected the basis of comparison (+16% in Q3 2015) and was mainly due to cognac, while the trend in champagne remained globally unchanged. Hennessy volumes only grew 9% over 9M vs +13% in H1. The group mentioned good growth in the US and improved momentum in China. It will provide the individual organic sales growth levels for cognac & spirits and champagne during the conference call due to be held at 3pm CET.
- The slowdown in the Wine & Spirits division should not be extrapolated to European spirits groups. Rémy Cointreau is set to publish its Q2 2016/17 sales on 18th October and should see a return to growth driven by its Cognac division. We expect total sales to rise 3.3% (+5% for Rémy Martin), accelerating vs Q1 (flat), which had been impacted by destocking. The performance by Pernod Ricard which is due to release its Q1 2016/17 sales on 20th October should also improve in China thanks to easy comps (-9% in Q1 2015/16) but is expected to remain in negative territory (an estimated -5%).

[Click here to download](#)

Virginie Roumage, vroumage@bryangarnier.com



## BG's Wake Up Call

# Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

### Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

### Distribution of stock ratings

BUY ratings 56.5%

NEUTRAL ratings 31.8%

SELL ratings 11.7%

## Bryan Garnier Research Team

Healthcare Team	Pharmaceuticals	Eric Le Berrigaud <i>(Head of Equities)</i>	33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
	Biotech/Medtech	Mickael Chane-Du	33 (0) 1 70 36 57 45	mchanedu@bryangarnier.com
	Medtech/Biotech	Hugo Solvet	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
Consumer Team	Luxury/Consumer Goods	Loïc Morvan	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
	Beverages	Nikolaas Faes	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
	Retailing	Antoine Parison	33 (0) 1 70 36 57 03	aparison@bryangarnier.com
	Luxury /Consumer Goods	Cedric Rossi	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
	Food & Beverages	Virginie Roumage	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
TMT	Video Games / Payments	Richard-Maxime Beaudoux	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
	Telecom	Thomas Coudry	33(0) 1 70 36 57 04	tcoudry@bryangarnier.com
	Software & IT Services	Gregory Ramirez	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
	Semiconductor	Dorian Terral	33 (0) 1 56 68 75 92	dterral@bryangarnier.com
Utilities		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
		Pierre-Antoine Chazal	33 (0) 1 56 68 75 06	pachazal@bryangarnier.com
Insurance		Olivier Pauchaut <i>(Head of Research)</i>	33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
Hotels/Business Services		Bruno de La Rochebrochard	33 (0) 1 56 68 75 88	bdelarochebrochard@bryangarnier.com
Construction/Infrastructures/Building Materials		Eric Lemarié	33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
Automotive & Parts		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
Marketing		Sophie Braincourt	33(0) 1 56 68 75 36	sbraincourt@bryangarnier.com
Market Data & Information Systems Manager		Eric Monnier	33(0) 1 56 68 75 63	emonnier@bryangarnier.com

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at [www.bryangarnier.com](http://www.bryangarnier.com)

London	Paris	New York	Munich
Beaufort House 15 St. Botolph Street London EC3A 7BB Tel: +44 (0) 207 332 2500 Fax: +44 (0) 207 332 2559 Authorised and regulated by the Financial Conduct Authority (FCA)	26 Avenue des Champs Elysées 75008 Paris Tel: +33 (0) 1 56 68 75 00 Fax: +33 (0) 1 56 68 75 01 Regulated by the Financial Conduct Authority (FCA) and the Autorité de Contrôle prudentiel et de résolution (ACPR)	750 Lexington Avenue New York, NY 10022 Tel: +1 (0) 212 337 7000 Fax: +1 (0) 212 337 7002 FINRA and SIPC member	Widenmayerstrasse 29 80538 Munich Germany <b>+49 89 2422 62 11</b>



## BRYAN, GARNIER & Co

### Disclaimer:

Bryan Garnier & Co Limited, registered in England Number 03034095 with registered office : Beaufort House 15 St Botolph Street, London EC3A 7BB , United Kingdom and its MIFID branch registered in France Number 452 605 512 with registered office : 26, Avenue des Champs Elysées 75008 Paris , France. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firms' prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

### Important information - This report may contain "Independent" and "Corporate/Non-independent" research reports.

Unless stated otherwise, documents in this report are classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

#### Independent investment research reports:

Independent investment research reports are prepared by Bryan Garnier & Co Limited and are distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports are provided for information purposes only and do not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person. The information and opinions contained in these reports have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in these reports are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of these reports. Information may be available to the Firm and/or associated companies which is not reflected in these reports. The Firm or an associated company may have a consulting relationship with a company which is the subject of these reports.

#### Corporate or Non-Independent investment research reports:

Non-independent research reports are prepared by Bryan Garnier & Co Limited and are being distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports have been sent to you for marketing purposes only and are non-independent research within the meaning of the FCA rules. These reports are not being held out as an objective or independent explanation of the matters contained in them and should not be treated as such. These reports have not been prepared in accordance with the legal requirements designed to promote the independence of investment research. The Firm is not subject to any prohibition on dealing ahead of the dissemination of investment research. These reports usually focus on emerging European growth companies. The contents of these reports as well as the other research documents on emerging growth stocks do not contain the Firm's usual stock ratings. The intrinsic value analysis is presented to provide a framework for stock valuation and discussion, and represents an estimated value on the date of publishing, which may be subject to change without notice.

The Firm's rationale for not having ratings on the stock includes the fact that such stock may have limited market capitalisation and liquidity and while the Firm may express an opinion on the near-term movement of the stock, what action investors should take depends on many factors, including liquidity/risk tolerance, holdings timeframe and investment philosophy. Emerging companies evolve rapidly with a continuous flow of information that can significantly impact the company and in the Firm's opinion this cannot be reflected by a periodic rating. Additionally, the Firm may have an advisory relationship with the company which is the subject of these reports, including for the production of sponsored research, and may expect to receive or intend to seek compensation for investment banking services from that company in the six months following the date of these reports.

To the fullest extent permitted by law, the Firm does not accept any liability whatsoever for any direct or consequential loss arising from any use of the information contained in these reports. Information may be available to the Firm which is not reflected in these reports. They are provided for information purposes only and do not constitute an offer or solicitation to buy or sell any of the securities discussed in them. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

#### Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

#### Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co. Ltd. believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co. Ltd. and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available....